Journal
BLOOD
Volume 124, Issue 20, Pages 3110-3117Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2014-04-569327
Keywords
-
Categories
Funding
- National Institutes of Health, National Cancer Institute [PO1-155258, RO1-124929, P50-100007, PO1-78378, RCA125711C]
- Wellcome Trust [077012/Z/05/Z]
- Wellcome Trust Senior Clinical Research Fellowship
- Lady Tata Memorial Trust
Ask authors/readers for more resources
Recent work has delineated mutational profiles in multiple myeloma and reported a median of 52 mutations per patient, as well as a set of commonly mutated genes across multiple patients. In this study, we have used deep sequencing of RNA from a subset of these patients to evaluate the proportion of expressed mutations. We find that the majority of previously identified mutations occur within genes with very low or no detectable expression. On average, 27%( range, 11% to 47%) of mutated alleles are found to be expressed, and among mutated genes that are expressed, there often is allele-specific expression where either the mutant or wild-type allele is suppressed. Even in the absence of an overall change in gene expression, the presence of differential allelic expression within malignant cells highlights the important contribution of RNA-sequencing in identifying clinically significant mutational changes relevant to our understanding of myeloma biology and also for therapeutic applications.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available